Zoetis Inc. (NYSE: ZTS), formerly the animal health business unit of Pfizer Inc., announced plans to expand its manufacturing facility in Lincoln, Neb., to facilitate the production of high-quality, reliable medicines for veterinarians, livestock producers and the animals under their care. A world leader in animal health, Zoetis expects this expansion to affirm its longstanding commitment to being a world-class manufacturer of animal health products as well as to continue to be an employer of choice in Lincoln. The plan calls for a 19,000 square-foot, three-story expansion of the existing production facility to accommodate the transfer of products from a third-party manufacturer to Lincoln. Early stages of planning and construction have begun and groundbreaking is expected to occur later this summer, initiating the start of the full construction phase. Zoetis expects to complete construction in 2014. This expansion will help ensure a reliable, consistent supply of quality medicines for animals. Today, Zoetis produces some of its flagship pharmaceutical products and vaccines at the Lincoln plant, including Bovi-Shield Gold® and RespiSure One® for livestock and Rimadyl® for dogs. The site is one of the largest internal manufacturing operations within Zoetis, employing more than 500 people today; the facility expansion could create as many as 30 new positions at peak production time. “Zoetis is excited about the opportunity to expand its manufacturing footprint in Lincoln and to leverage the expertise in high-quality manufacturing that our colleagues have demonstrated in Lincoln for decades,” said Michael Morgan, site leader in Lincoln. Zoetis and its predecessors have long held a presence in the Lincoln area. In the early 20 th century, drug firms and distributors such as Norden Laboratories established facilities in Nebraska that evolved over time. Since then, more recent incarnations of these animal health companies, including the Zoetis facility, have continued to serve as an important part of the Lincoln community. The Lincoln facility is a key site in Zoetis’ global manufacturing network and one of the largest suppliers of Zoetis’ animal health products for the world. It has been in operation at its current location since 1961, producing 1,200 finished goods for more than 100 markets annually. “This expansion shows our continuing commitment to the Lincoln community, a community that we have been a part of for several decades. We are proud of our new name, Zoetis, and look forward to continuing to produce great quality medicines and vaccines for our customers,” said Morgan.